Literature DB >> 17164543

Clinicopathological characteristics and prognosis of carcinoma of the gastric cardia.

Dong Yi Kim1, Jae Kyoon Joo, Seong Yeob Ryu, Young Kyu Park, Young Jin Kim, Shin Kon Kim.   

Abstract

OBJECTIVE: The prognosis of patients with carcinoma of the gastric cardia (CGC) is poorer than that of patients with distal third gastric carcinoma (DTGC). The main aim of this study is to investigate whether the tumor location is an important prognostic factor.
METHODS: 312 patients (8.1%) were diagnosed with CGC and reviewed retrospectively.
RESULTS: T1 stage tumors were less common in patients with CGC than in those with DTGC (p< 0.001). Lymph node invasion was more common in CGC patients than in DTGC patients (p< 0.01). Multivariate analysis showed that patient age, lymph node status, and resection with curative intent were significant prognostic factors for the survival of CGC patients. Of the patients who underwent tumor resection with curative intent, the 5-year survival rate of CGC patients was lower than that of DTGC patients (57.4 vs. 63.1%), but no significant difference was observed between the two groups (p> 0.05). When the CGC group was divided into patients who underwent resection with or without curative intent, the 5-year survival rates were 52.8 and 6.0%, respectively (p< 0.001).
CONCLUSION: According to our results, curative resection itself, rather than tumor location, was the determining factor in improving 5-year survival. Copyright 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2006        PMID: 17164543     DOI: 10.1159/000097895

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  8 in total

1.  Effect of lymphadenectomy extent on advanced gastric cancer located in the cardia and fundus.

Authors:  Chang-Ming Huang; Bi-Juan Lin; Hui-Shan Lu; Xiang-Fu Zhang; Ping Li; Jian-Wei Xie
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

2.  Prognostic impact of metastatic lymph node ratio in advanced gastric cancer from cardia and fundus.

Authors:  Chang-Ming Huang; Bi-Juan Lin; Hui-Shan Lu; Xiang-Fu Zhang; Ping Li; Jian-Wei Xie
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

3.  DO PROXIMAL AND DISTAL GASTRIC TUMOURS BEHAVE DIFFERENTLY?

Authors:  Laurence Bedin da Costa; Marcelo Garcia Toneto; Luis Fernando Moreira
Journal:  Arq Bras Cir Dig       Date:  2016 Nov-Dec

4.  Disparities and survival in newly diagnosed gastric cancer in Hispanic patients in the United States: a propensity score matched analysis.

Authors:  Joshua Tseng; James P Miller; Jeffrey Johnson; Kevin Waters; Alexandra Gangi; Jun Gong; Miguel Burch
Journal:  J Gastrointest Oncol       Date:  2021-08

5.  An orthotopic nude mouse model for preclinical research of gastric cardia cancer.

Authors:  Sarah Bhargava; Birgit Hotz; Heinz J Buhr; Hubert G Hotz
Journal:  Int J Colorectal Dis       Date:  2008-09-30       Impact factor: 2.571

6.  Clinicopathological Features of Upper Third Gastric Cancer during a 21-Year Period (Single Center Analysis).

Authors:  Je-Ho Jang; Reinaldo Isaacs Beron; Hye Seong Ahn; Seong-Ho Kong; Hyuk-Joon Lee; Woo-Ho Kim; Kuhn Uk Lee; Han-Kwang Yang
Journal:  J Gastric Cancer       Date:  2010-12-31       Impact factor: 3.720

7.  Clinicopathologic characteristics in patients with upper third gastric cancer following radical surgical treatment: A retrospective cohort study.

Authors:  Xiaoming Ma; Wei Zhou; Cheng Wang; Wei Miao; Ning Liu; Shigui Wang; Shihao Guan
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

8.  Comparison on Clinicopathological Features and Prognosis Between Esophagogastric Junctional Adenocarcinoma (Siewert II/III Types) and Distal Gastric Adenocarcinoma: Retrospective Cohort Study, a Single Institution, High Volume Experience in China.

Authors:  Kai Liu; Weihan Zhang; Xiaolong Chen; Xinzu Chen; Kun Yang; Bo Zhang; Zhixin Chen; Zongguang Zhou; Jiankun Hu
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.817

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.